Skip to main content

Table 4 Analysis of change (delta values) of outcomes at study time points a

From: A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects

Test Treatment Delta value T1bversus T2c Delta value T2 versus T3d Delta value T1 versus T3
ADAS-Cog e IFNβ 1a 0.144 ± 1.16 −2.17 ± 1.01 (p = 0.031) −2.02 ± 1.58
Placebo 2.25 ± 1.05 −2.78 ± .1.02 −0.52 ± 1.86
MMSE f IFNβ 1a 0.78 ± 0.52 −1.81 ± 0.69 (p = 0.037) −1.02 ± 1.03
Placebo 0.73 ± 0.98 −1.68 ± 0.76 −0.95 ± 1.0
ADAS-NonCog g IFNβ 1a −0.26 ± 0.53 −0.84 ± 0.35 −1.10 ± 0.65
Placebo 0.86 ± 0.75 −2.0 ± 1.099 −1.13 ± 1.26
PSMS h IFNβ 1a 0.31 ± 0.23 1.05 ± 0.66 (p = 0.0459) 1.36 ± 0.76 (p = 0.025)
Placebo 0.6 ± 0.6 −0.13 ± 0.29 0.46 ± 0.33
GDS i IFNβ 1a 0.42 ± 0.94 −1.10 ± 0.79 −0.68 ± 1.35
Placebo 2.0 ± 1.34 1.57 ± 0.83 (p = 0.0418) 3.57 ± 1.24 (p = 0.009)
Global DS j IFNβ 1a −0.05 ± 0.17 −0.21 ± 0.12 −0.26 ± 0.18
Placebo −0.13 ± 0.13 −0.2 ± 0.10 −0.33 ± 0.15
IADL k IFNβ 1a 0.26 ± 0.34 0.94 ± 0.37 (p = 0.0306) 1.20 ± 0.59 (p = 0.041)
Placebo 0.6 ± 0.36 −0.06 ± 0.18 0.53 ± 0.36
  1. aValues are shown as means ± SEM; Negative change indicates worsening of condition. In brackets are reported p values (by arm) when statistically significant. bT1 = baseline (week 0); cT2 = end of treatment (week 28); dT3 = follow-up (week 54). eADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; fMMSE, Mini Mental State Examination; gADAS-Non-Cog, Alzheimer’s Disease Assessment Scale-Non-Cognitive Section; hPSMS, Physical Self-Maintenance Scale; iGDS, Geriatric Depression Scale; Global, jGlobal Deterioration Scale (DS) for Assessment of Primary Degenerative Dementia; kIADL, Instrumental Activities of Daily Living Scale.